Marshall Wace
CLDI icon

Marshall Wace’s Calidi Biotherapeutics CLDI Stock Holding History

Marshall Wace’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-516
Closed -$12.4K – 2556
2024
Q2 		$12.4K Hold
516
– – ﹤0.01% 2476
2024
Q1 		$35.3K Buy
+516
New +$52.7K ﹤0.01% 2359
2022
Q3 		– Sell
-8,852
Closed -$10.6M – 3388
2022
Q2 		$10.6M Hold
8,852
– – 0.02% 833
2022
Q1 		$10.5M Hold
8,852
– – 0.02% 841
2021
Q4 		$10.4M Buy
+8,852
New +$10.4M 0.02% 835

Other funds holding CLDI

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Marshall Wace's CLDI Position: Q3 2024 in Review

Marshall Wace sold out of Calidi Biotherapeutics (CLDI) in Q3 2024, closing a stake of 516 shares — an estimated $12.4K sold.

Marshall Wace first reported a position in CLDI in Q4 2021 and held it in 5 quarters. The position peaked at $10.6M in Q2 2022. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2024.

  • Marshall Wace reported no remaining Calidi Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Marshall Wace sold 516 Calidi Biotherapeutics shares in Q3 2024, an estimated $12.4K.
  • Marshall Wace first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Marshall Wace's Calidi Biotherapeutics position peaked at $10.6M in Q2 2022.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2024.

Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.